Bayerische Motoren Werke ADR (BMWYY)

LIXTE Biotechnology Holdings (NASDAQ: LIXT), a clinical-stage pharmaceutical company, is in the unique position of holding the world’s only clinical-stage protein phosphatase 2A (“PP2A”) inhibitor, called LB-100.

A team of scientists from Texas Children’s Hospital, University of Pittsburgh and Baylor College of Medicine has discovered the primary driver of a deadly pediatric brain cancer, PFA (posterior fossa type A) ependymoma. They identified male sex hormones called androgens as playing a key role in promoting PFA ependymoma growth.

Nutriband (NASDAQ: NTRB) announced it has selected a proposed worldwide brand name for its abuse-deterrent fentanyl transdermal system, with plans to submit the name and product labeling to the FDA and international regulators as well as file for trademark protection. The company said the product, developed using its AVERSA(TM) technology, could become the first abuse-deterrent fentanyl patch designed to reduce misuse and accidental exposure, targeting a potential peak annual U.S. market of $80 million to $200 million while addressing broader global pain management needs.

Lantern Pharma (NASDAQ: LTRN) reported fourth-quarter and full-year 2025 operational highlights led by continued progress in its LP-300 Phase 2 HARMONIC trial, completion of targeted enrollment in Japan, planned protocol discussions with the FDA in mid-May 2026 and advancement of LP-184, LP-284 and STAR-001 across multiple oncology indications. The company said its AI-driven portfolio now targets an estimated annual market opportunity of more than $15 billion, while its RADR(R) platform and newly introduced withZeta.ai multi-agentic co-scientist platform are expanding commercial potential, with beta testing underway at more than 25 biotech companies, cancer research centers and biopharma consultants, as Lantern ended 2025 with approximately $10.1 million in cash, cash equivalents and marketable securities.

Modern problems require modern solutions, and that's what Detroit automakers are currently figuring out in China.

Researchers seeking new ways of fighting cancer using immunotherapy have discovered a “hidden brake” that had previously been unknown to scientists. This brake exists on immune cells and scales back their ability to combat cancer, and it acts without any influence from tumor cells.

Lixte Biotech Holdings (NASDAQ: LIXT) is advancing the frontiers of precision oncology, developing therapies that complement existing cancer treatments while integrating cutting-edge data solutions. The company’s lead program, LB-100, is a novel small-molecule compound designed to enhance the efficacy of chemotherapy and radiation, aiming to improve patient outcomes while reducing treatment-related side effects. By focusing on improving the therapeutic index of existing cancer modalities, the company is tackling a recurrent challenge in the field of oncology: maximizing treatment impact while cutting down risks to healthy tissue.

NextPlat (NASDAQ: NXPL, NXPLW) announced a collaboration with HealthWarehouse.com Inc. (OTCQB: HEWA) to enable nationwide fulfillment of prescription and over-the-counter products, significantly expanding its U.S. healthcare footprint beyond Florida. The partnership allows NextPlat’s PharmcoRx division to deliver medications across all 50 states through HealthWarehouse’s licensed digital pharmacy platform, supporting broader e-commerce expansion and positioning the company to scale revenue growth and healthcare access in 2026.

On Tuesday this week, researchers revealed that a group of hackers linked to the Iranian government had targeted another United States medical institution toward the end of February prior to the onset of the current military conflict between the U.S., Israel and Iran. This is the second such attack .

German automakers are facing one of the most important moments in their history as the global shift to electric vehicles continues to grow. Companies like Volkswagen, Mercedes-Benz, BMW, and Porsche are now under pressure to adapt quickly or risk falling behind.

Earth Science Tech (OTC: ETST) is consolidating on its identity as a leading healthcare holding company, implementing a strategy built on vertical integration across telemedicine, pharmaceuticals, and clinical services. The company’s transitioning from legacy operations highlights a distinct alignment with high-growth segments of the healthcare sector, particularly personalized medicine and digital care delivery ( ibn.fm/9lMJg ).

As electric vehicle adoption accelerates across Southwest Ohio, BMW of Cincinnati North has launched a new online EV education guide to help Cincinnati-area drivers understand charging options, ownership costs, and the long-term benefits of driving a BMW electric vehicle.

HeartBeam (NASDAQ: BEAT) recently announced a collaboration with Mount Sinai aimed at advancing artificial intelligence-driven electrocardiogram technology, marking another step in the company’s push to expand its role in next-generation cardiac monitoring. The announcement highlights HeartBeam’s growing focus on artificial intelligence (“AI”)-enabled analysis and reinforces the relevance of its technology as healthcare increasingly shifts toward data-driven, remote monitoring solutions.

As of March 24, 2026, the global energy transition has reached a critical inflection point, and at the heart of this shift stands Albemarle Corporation (NYSE: ALB). After weathering a tumultuous two-year period defined by a "lithium winter" that saw prices plummet from historic highs, Albemarle has emerged in 2026 as a leaner, more strategically [...]

As of March 24, 2026, Tesla, Inc. (NASDAQ: TSLA) finds itself at a pivotal crossroads, navigating a landscape that looks vastly different from the unbridled growth years of the early 2020s. Once the undisputed monarch of the electric vehicle (EV) revolution, the Austin-based titan is currently grappling with a significant "European Slump"—a contraction in its [...]

For a long time, scientists have been working tirelessly to come up with vaccines against cancer. Significant progress is being registered in developing mRNA vaccines against cancer, but this progress has come up against a wall of misinformation that could thwart the prospects of this promising intervention.

Gaxos.ai (NASDAQ: GXAI) announced that its portfolio company, America First Defense (AFD), has begun deployment of the Anduril Lattice Platform to expand its counter-swarm UAV and anti-drone defense systems, marking a key milestone in advancing its autonomous defense infrastructure. The integration enhances AFD’s ability to identify, track, assess and respond to evolving unmanned aerial threats, supporting its focus on layered, AI-enabled counter-UAS solutions as demand grows for adaptive, software-defined defense technologies.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing therapies for rare diseases and unmet medical needs, is featured in a detailed research report issued by Zacks Small-Cap Research. The March 12 report provides a comprehensive look at the company’s pipeline, financial positioning and upcoming clinical catalysts, underscoring the potential value proposition for investors as Soligenix advances multiple programs toward key inflection points.

Regulatory recognition from international health authorities can significantly shape the trajectory of emerging therapies worldwide, particularly in rare disease development where clinical pathways are often complex and resource intensive. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases and unmet medical needs, recently received such recognition as its investigational therapy SGX945 was granted Promising Innovative Medicine (“PIM”) designation by the United Kingdom’s (“UK’s”) Medicines and Healthcare products Regulatory Agency (“MHRA”).

As of March 20, 2026, NVIDIA Corporation (NASDAQ:NVDA) has transcended its origins as a high-end graphics chipmaker to become the foundational architect of the global digital economy. Often referred to by analysts as the "Operating System of AI," NVIDIA’s influence now rivals that of the great industrial giants of the 20th century. The company’s trajectory [...]

Enormous resources are being channeled into studying different ways to support the immune system in its fight against cancer. One emerging approach is the use of oncolytic viruses. This approach seeks to leverage viruses to destroy cancer by attacking and killing its cells.

Tesla investors knew they'd be seeing some new competitors -- but many didn't expect this one.

David Eby, the Premier of British Columbia, has revealed that a wide range of American healthcare workers, including doctors, nurse practitioners and nurses have flocked to the Canadian province in search of employment and have secured jobs.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, announced a partnership with NeuroRPM to implement an FDA-cleared AI platform in its ongoing Parkinson’s disease study, enabling real-time monitoring of symptoms such as bradykinesia, tremor and dyskinesia through wearable and mobile technology, with the data serving as digital biomarkers to enhance disease tracking, support evaluation of buntanetap over the 36-month trial and provide deeper insights into treatment response and future clinical development.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced it will host a conference call at 8:00 a.m. ET on March 24, 2026, to review financial results for the fiscal year ended Dec. 31, 2025, and provide updates on progress across its drug development programs and the HOPE Therapeutics clinical network, highlighting milestones aligned with its mission to prevent suicide and advance treatments for depression and PTSD.